GLPwatch
Papers (9189)
Page 109 of 154, ranked by citation count.
- Is treatment with liraglutide efficient?
- Direct Effect of the Synthetic Analogue of Glucagon-Like Peptide Type 1, Liraglutide, on Mature Adipocytes Is Realized through Adenylate-Cyclase-Dependent Enhancing of Insulin Sensitivity.
- The association between previous use of anti-obesity medication and semaglutide weight loss outcomes.
- Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study.
- First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
- Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus.
- In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk.
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
- Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies.
- Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
- A Pair of Siblings With Wolfram Syndrome: A Review of the Literature and Treatment Options.
- Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.
- Potential Role of Hypothalamic and Plasma Ghrelin in the Feeding Behavior of Obese Type 2 Diabetic Rats with Intraventricular Glucagon-Like Peptide-1 Receptor Agonist Intervention.
- Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis.
- Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.
- Tirzepatide for diabetes: on track to SURPASS current therapy.
- iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data.
- Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss.
- Mechanism of and strategy to mitigate liraglutide-mediated positive chronotropy.
- A Liraglutide Injection Superimposing a Starvation Acidosis: a Case Report.
- Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial.
- Efficacy of liraglutide intervention in myocardial infarction : A meta-analysis of randomized controlled trials.
- Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide.
- Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
- Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist.
- Systemic semaglutide provides a mild vasoprotective and antineuroinflammatory effect in a rat model of ocular hypertensive glaucoma.
- Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers.
- The GLP-1 Receptor Agonist Liraglutide Decreases Primary Bile Acids and Serotonin in the Colon Independently of Feeding in Mice.
- Therapeutic effects of exendin-4 on spinal cord injury via restoring autophagy function and decreasing necroptosis in neuron.
- Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria.
- Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis.
- Liraglutide enhances myotube differentiation and muscle contractile activity upon electric pulse stimulation in mouse skeletal muscle cells.
- Divergent effects of exendin-4 and interleukin-6 on rat colonic secretory and contractile activity are associated with changes in regional vagal afferent signaling.
- Acquisition of absorption-enhancing abilities of cationic oligopeptides with short chain arginine residues through conjugation to hyaluronic acid.
- Improvement in body mass index category was associated with improved cardiometabolic measures and patient-reported outcomes in adults with type 2 diabetes treated with tirzepatide.
- Brown Adipose Tissue Mimicking Head and Neck Cancer on PET Scan in a Patient on GLP-1 Drug.
- Glucagon‑like peptide‑1 analogue exendin‑4 modulates serotonin transporter expression in intestinal epithelial cells.
- Facilitated structure verification of the biopharmaceutical peptide exenatide by 2D heteronuclear NMR maps.
- Plastic surgery amid a semaglutide epidemic: Direction for future studies and service implications.
- Liraglutide alleviated alpha-pyrrolidinovalerophenone (α-PVP) induced cognitive deficits in rats by modifying brain mitochondrial impairment.
- Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report.
- Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
- Blood pressure changes during smoking cessation in a randomized, double-blind, placebo-controlled trial of dulaglutide treatment.
- Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.
- New antihyperglycaemic agents and cardiovascular disease: let's be optimistic.
- Maternal Weight Intervention in the Perinatal Period Improves Liver Health in the Offspring of Mothers with Obesity.
- The safety of albiglutide for the treatment of type 2 diabetes.
- Exendin-4, a glucagon-like peptide-1 receptor agonist, regulates ductus arteriosus by vasodilation and anti-remodeling through the PKA pathway.
- The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
- Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study.
- Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.
- Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line.
- Conjugation to a cell-penetrating peptide drives the tumour accumulation of the GLP1R antagonist exendin(9-39).
- Suppression of the nuclear factor Eny2 increases insulin secretion in poorly functioning INS-1E insulinoma cells.
- Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity.
- Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study.
- GLP-1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis.
- Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders.
- [Injection of submandibular gland with recombinant Exendin-4 and adeno-associated virus for the treatment of diabetic rats].
- The GLP1R Agonist Semaglutide Inhibits Reactive Astrocytes and Enhances the Efficacy of Neural Stem Cell Transplantation Therapy in Parkinson's Disease Mice.